Retatrutide
Triple-agonist GLP-1/GIP/Glucagon. The most powerful weight loss peptide ever studied.
Last updated: May 2026
Category
Weight Loss (GLP-1/GIP/Glucagon)
Frequency
Once weekly injection
Research
Phase 3 Clinical TrialsWhat is Retatrutide?
Retatrutide is a novel triple-agonist peptide developed by Eli Lilly that simultaneously activates three metabolic receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This triple-action mechanism makes it the most potent weight loss compound ever studied in clinical trials.
In a Phase 2 trial published in the New England Journal of Medicine (2023), participants on the highest dose (12mg) achieved an average body weight reduction of 28.7% over 48 weeks, more than double the effect of early GLP-1 drugs. This has made Retatrutide highly sought after in the biohacking and weight loss communities, including in Vietnam.
While not yet FDA approved (currently in Phase 3 trials), research-grade retatrutide is widely available through peptide suppliers. Users consistently report dramatic fat loss with good tolerability, particularly compared to semaglutide. Browse all weight loss peptide options to compare, or verify your supplier with the COA verification guide.
How It Works
GLP-1 Agonism: Activates GLP-1 receptors in the brain and pancreas to suppress appetite, slow gastric emptying, and improve insulin secretion. This is the same mechanism as Ozempic and Mounjaro.
GIP Agonism: Activates GIP receptors which synergize with GLP-1 to enhance insulin response and are thought to reduce the nausea commonly associated with GLP-1 drugs alone.
Glucagon Agonism: This is what makes Retatrutide unique. Glucagon agonism directly increases metabolic rate (thermogenesis) and enhances fat oxidation, particularly visceral fat. This explains the superior weight loss results compared to dual-agonists.
Benefits
- 28.7% average body weight reduction in Phase 2 trials (highest ever recorded)
- Significant visceral fat reduction due to glucagon receptor activation
- Improved insulin sensitivity and metabolic health markers
- Reduced appetite and food cravings (often dramatically so)
- Possible improvements in cardiovascular risk factors
- Once-weekly dosing for convenience
- Reported reduction in "food noise": obsessive thoughts about eating
Dosing Protocol
| Phase | Dose | Frequency | Duration |
|---|---|---|---|
| Starting | 2mg | Once weekly | Weeks 1–4 |
| Titration 1 | 4mg | Once weekly | Weeks 5–8 |
| Titration 2 | 8mg | Once weekly | Weeks 9–16 |
| Maintenance | 8–12mg | Once weekly | Ongoing |
Always start at the lowest effective dose and titrate up gradually.
Side Effects
Common
- ⚠Nausea (most common, especially when titrating up)
- ⚠Vomiting (usually resolves with slower titration)
- ⚠Decreased appetite
- ⚠Diarrhea or constipation
- ⚠Fatigue in first few weeks
- ⚠Injection site reactions (redness, bruising)
Rare
- •Pancreatitis (discontinue immediately if severe abdominal pain)
- •Gallbladder issues
- •Heart rate increase
- •Hair loss (associated with rapid weight loss, not the peptide itself)
Who Should NOT Use Retatrutide
- ✕Personal or family history of medullary thyroid carcinoma (MTC)
- ✕Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- ✕History of pancreatitis
- ✕Type 1 diabetes
- ✕Pregnancy or breastfeeding
- ✕Severe gastrointestinal disease
- ✕Under 18 years old
What to Expect
Nausea is common as your body adjusts. Appetite begins to decrease. Some report feeling full very quickly after eating small amounts.
Nausea typically subsides. Food noise begins to quiet. First noticeable weight loss (often 1–3kg) from caloric restriction.
Steady weight loss continues (typically 1–2kg/week when combined with modest dietary improvements). Energy often improves.
Most users report being at or near their maintenance phase. Weight loss slows as body composition improves. Visceral fat reduction becomes visible.
Notes from Ho Chi Minh City
Retatrutide is the Phase 3 compound I would not run if you have not already cycled through semaglutide and tirzepatide first, because the appetite suppression at 4mg weekly is severe enough that protein intake becomes a deliberate engineering problem rather than something you can default to. The Tet weight regain pattern in HCMC where you drift up 4 to 6kg between January and February is exactly the use case retatrutide is built for; one 8-week cycle starting late February pulls it back faster than tirzepatide does. Sourcing in Vietnam is research-grade only since brand pens are not yet approved by the DAV, and the cold-chain importer route runs roughly 3 to 5 million VND per 10mg vial. The triple agonist mechanism means GI side effects are more pronounced for the first two weeks, so titrate slowly.
Sourcing in Vietnam
Retatrutide is not approved by Vietnam's Drug Administration (DAV) and is not stocked at Long Châu, Pharmacity, or any retail pharmacy. The only sourcing route is research-grade vials through cold-chain importers (3 to 5 million VND per 10mg vial). See the Retatrutide Vietnam 2026 guide for full sourcing details and the calculator for weight-loss timeline estimates.
FAQ
Q: Is Retatrutide legal in Vietnam?
A: Retatrutide exists in a gray area. It is not approved as a pharmaceutical in Vietnam, but personal-use importation is not explicitly prohibited. Most users obtain it through research peptide suppliers. For current legal status, sourcing options, and COA red flags specific to Vietnam, see the Retatrutide Vietnam 2026 guide. Always consult a healthcare professional.
Q: How does Retatrutide compare to Tirzepatide?
A: Retatrutide adds glucagon agonism on top of the GLP-1+GIP mechanism of Tirzepatide, which drives additional metabolic rate increase and fat oxidation. Clinical trials show roughly 6–8% more weight loss with Retatrutide vs Tirzepatide at comparable doses.
Q: Do I need to diet while using Retatrutide?
A: The appetite suppression is so strong that most users naturally eat less without consciously dieting. However, maintaining protein intake (1.6g/kg bodyweight) is critical to prevent muscle loss during rapid weight reduction.
Q: How long should I use Retatrutide?
A: Most users use it for 3–6 months to reach their goal weight, then either discontinue (with lifestyle changes to maintain) or continue at a lower maintenance dose. Weight typically returns if discontinued without behavioral changes.
Where to Get Retatrutide in Vietnam
Retatrutide is not available at any Vietnamese pharmacy or clinic. It remains a Phase 3 investigational compound globally. Research-grade sourcing is the only path. For Vietnam pricing, supplier verification, and COA red flags, see our Retatrutide Vietnam 2026 guide. For the legal status of research peptides in Vietnam, see our legality guide. Then browse the community-verified supplier list.
Related Peptides
Related Guides
Research & Sources
- Triple Hormone Receptor Agonist Retatrutide for Obesity (Phase 2 trial) · Jastreboff AM, Kaplan LM, Frias JP, et al. · New England Journal of Medicine (2023) PMID: 37366315
Phase 2 trial showing 24.2% mean weight loss at 48 weeks on retatrutide 12mg weekly.
- Triple agonist of GIP, GLP-1 and glucagon receptors: a novel approach to obesity and diabetes treatment · Coskun T, Urva S, Roell WC, et al. · Cell Metabolism (2022) PMID: 35421379
Foundational pharmacology of the GIP/GLP-1/glucagon triple agonism unique to retatrutide.
- Retatrutide once weekly for the treatment of obesity in people with type 2 diabetes · Rosenstock J, Frias J, Jastreboff AM, et al. · The Lancet (2023) PMID: 37385275
Phase 2 efficacy data in T2D patients showing weight loss and glycemic improvements.
- Pharmacokinetics and pharmacodynamics of retatrutide in healthy adults · Urva S, Coskun T, Loh MT, et al. · Clinical Pharmacology in Drug Development (2022) PMID: 35671067
PK/PD data supporting once-weekly dosing rationale and titration schedule.
Important Disclaimer
Educational content only. Not medical advice. Peptides discussed on this page are not approved by Vietnam’s Ministry of Health (Bộ Y Tế) or the Drug Administration of Vietnam (DAV) for the indications described. Research peptides are not stocked at Long Châu, Pharmacity, or any retail pharmacy in Vietnam. Consult a licensed physician before any use.